Study on Diaphragmatic Function After Interscalene Brachial Plexus Block Using Liposomal Bupivacaine Compared to Standard Bupivacaine in Upper Limb Surgery

What this Trial Is About

This research aims to evaluate the effects of Liposomal Bupivacaine on diaphragmatic function in patients undergoing upper limb surgery who receive an interscalene brachial plexus block. The study involves 120 eligible patients divided into two groups to compare different anesthetic approaches. The goal is to assess the recovery time of diaphragmatic and pulmonary function after this type of nerve block, which may cause temporary diaphragmatic paralysis. Participants are assigned to one of two groups Group A receives 20 ml of 0.5% Hydrochloride Bupivacaine alone, while Group B receives a combination of 10 ml of 0.5% Hydrochloride Bupivacaine plus 10 ml of Liposomal Bupivacaine. The study monitors diaphragmatic and pulmonary function, as well as pain intensity, before and at multiple time points after the nerve block. Follow-up includes assessment for any adverse events, with the study running from December 2025 to August 2026. During the study, participants undergo repeated evaluations of their diaphragmatic and pulmonary function within approximately 72 hours after the nerve block. Researchers measure the recovery time of diaphragmatic function, incidence of hemidiaphragmatic paralysis at different times, and the proportion of pulmonary function recovery. The study follows ethical guidelines and protects participant privacy throughout the trial duration.

Evaluation of Diaphragmatic Function After Interscalene Block With Liposomal Bupivacaine